Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director | June 11, 2026 | June 12, 2026 |
| Atreca, Inc.BCEL · Entity 91940 | Director | June 13, 2023 | June 15, 2023 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | Director | June 18, 2020 | June 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,652 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,700 · Balance 76,652 F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2036-06-10 | Direct | 16,900 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 16,900 · Balance 16,900 F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Atreca, Inc.
Report date June 13, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2023-06-12 | Direct | 12,000 |
Reported balance
After 2023-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 12,000 · Balance 12,000 F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Unity Biotechnology, Inc.
Report date June 18, 2020 · Filed June 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.14 · Expires 2030-06-17 | Direct | 25,000 |
Reported balance
After 2020-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-18 · Grant · Acquired 25,000 · Balance 25,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 18, 2020 or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 18, 2020 or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 16,900 | $0.00 Strike: $23.30 | $0.00 |
DisclosureSEC source: 0001734422-26-000005 · wk-form4_1781296084.xml · derivative · entry 2 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,900 Underlying: Stock Option (Rights to Buy) · 16,900 shares Expires 2036-06-10 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 5,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001734422-26-000005 · wk-form4_1781296084.xml · nonDerivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,652 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| May 15, 2026 Filed May 15, 2026 21:51 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $15.86 | $0.00 |
DisclosureSEC source: 0001734422-26-000002 · wk-form4_1778881888.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2036-05-14 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 38,300 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001724521-25-000088 · wk-form4_1749760091.xml · derivative · entry 2 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2035-06-09 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000088 · wk-form4_1749760091.xml · nonDerivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,952 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| May 19, 2025 Filed May 19, 2025 21:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0001549595-25-000079 · wk-form4_1747690372.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001724521-25-000015 · wk-form4_1738013395.xml · derivative · entry 2 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-01-22 F1 · derivative.exercise_date: The option is exercisable in 24 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 22:20 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001724521-24-000115 · wk-form4_1717798846.xml · derivative · entry 2 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-06-05 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 22:20 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000115 · wk-form4_1717798846.xml · nonDerivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,652 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| May 20, 2024 Filed May 20, 2024 23:25 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001549595-24-000066 · wk-form4_1716247526.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-19 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 20, 2025, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001209191-23-038145 · doc4.xml · derivative · entry 2 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2033-06-14 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 6,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038145 · doc4.xml · nonDerivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,252 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 18:07 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-23-037518 · doc4.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2023-06-12 F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. Read SEC document |
| May 04, 2023 Filed May 4, 2023 23:57 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-23-027508 · doc4.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 4, 2024, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 16,800 | $0.00 Strike: $20.62 | $0.00 |
DisclosureSEC source: 0001209191-22-037412 · doc4.xml · derivative · entry 2 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 16,800 shares Expires 2032-06-13 F3 · derivative.exercise_date: The option will vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037412 · doc4.xml · nonDerivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,452 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2022. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 18:45 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-22-036105 · doc4.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-22-027666 · doc4.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-04 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 5, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 16:33 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $10.27 | $0.00 |
DisclosureSEC source: 0001209191-21-039845 · doc4.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:38 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-21-038623 · doc4.xml · derivative · entry 2 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2031-06-02 F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:38 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038623 · doc4.xml · nonDerivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,352 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| May 06, 2021 Filed May 24, 2021 23:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $27.38 | $0.00 |
DisclosureSEC source: 0001209191-21-035539 · doc4.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-05-05 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 17:27 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0000899243-20-017393 · doc4.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 18, 2020 or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document |
| June 10, 2020 Filed Jun 15, 2020 17:07 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $17.87 | $0.00 |
DisclosureSEC source: 0001209191-20-036664 · doc4.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:20 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $36.34 | $0.00 |
DisclosureSEC source: 0001209191-20-032004 · doc4.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The option is exercisable in 36 equal monthly installments after May 21, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 16:11 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013866 · doc1.xml · derivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 20, 2019 or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Non-Employee Director until such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.